Business Combination - Schedule of Identifiable Intangible Assets Acquired (Details) - Avadel Pharmaceuticals Plc $ in Thousands |
Feb. 12, 2026
USD ($)
|
|---|---|
| Business Combination [Line Items] | |
| LUMRYZ | $ 1,768,600 |
| In-process research and development | 26,300 |
| Total identifiable intangible assets | $ 1,794,900 |
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of identifiable intangible asset acquired in business combination and recognized at acquisition date. Excludes goodwill and financial asset. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of increase in finite-lived intangible asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of increase in indefinite-lived asset acquired in business combination, asset acquisition, and from joint venture formation. Excludes goodwill. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Details
|